In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Brainsway nets $25.6mm through IPO of ADSs on Nasdaq

Executive Summary

In its second attempt to list on Nasdaq, Brainsway Ltd. (deep transcranial magnetic stimulation device (TMS) for psychiatric, neurological, and addiction disorders) netted $25.6mm through its initial public offering of 2.5mm American Depositary Shares (ADSs, with each representing two ordinary shares) at $11 (or $5.50/share). Earlier this month the company announced it planned to sell 2.5mm ADSs at $11.94 apiece, or $5.97/share.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies